{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T04:27:53Z","timestamp":1779337673305,"version":"3.51.4"},"reference-count":184,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004173","name":"Universidad Aut\u00f3noma Metropolitana","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004173","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003141","name":"Consejo Nacional de Humanidades, Ciencias y Tecnolog\u00edas","doi-asserted-by":"publisher","award":["815062"],"award-info":[{"award-number":["815062"]}],"id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003141","name":"Consejo Nacional de Humanidades, Ciencias y Tecnolog\u00edas","doi-asserted-by":"publisher","award":["815405"],"award-info":[{"award-number":["815405"]}],"id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.lfs.2025.123638","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T13:55:36Z","timestamp":1744725336000},"page":"123638","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Update in non-alcoholic fatty liver disease management: role of sodium-glucose cotransporter 2 inhibitors"],"prefix":"10.1016","volume":"372","author":[{"given":"Oscar R.","family":"Zambrano-V\u00e1squez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Cort\u00e9s-Camacho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge I.","family":"Casta\u00f1eda-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Ar\u00e9chaga-Ocampo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Estefan\u00eda","family":"Valle-Vel\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan C.","family":"Cabrera-Angeles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 L.","family":"S\u00e1nchez-Gloria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fausto","family":"S\u00e1nchez-Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abraham S.","family":"Arellano-Buendia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura G.","family":"S\u00e1nchez-Lozada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Horacio","family":"Osorio-Alonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.lfs.2025.123638_bb0005","article-title":"Non-alcoholic fatty liver disease: a patient guideline","volume":"3","author":"Francque","year":"2021","journal-title":"JHEP Rep."},{"issue":"10290","key":"10.1016\/j.lfs.2025.123638_bb0010","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.lfs.2025.123638_bb0015","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.lfs.2025.123638_bb0020","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1016\/j.jhep.2023.08.026","article-title":"99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical","volume":"80","author":"Hagstr\u00f6m","year":"2024","journal-title":"J. Hepatol."},{"issue":"7","key":"10.1016\/j.lfs.2025.123638_bb0025","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1053\/j.gastro.2020.01.052","article-title":"Nonalcoholic fatty liver disease 2020: the state of the disease","volume":"158","author":"Cotter","year":"2020","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.lfs.2025.123638_bb0030","doi-asserted-by":"crossref","first-page":"382","DOI":"10.4093\/dmj.2020.0010","article-title":"Non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: a position statement of the fatty liver research Group of the Korean Diabetes Association","volume":"44","author":"Lee","year":"2020","journal-title":"Diabetes Metab. J."},{"issue":"1","key":"10.1016\/j.lfs.2025.123638_bb0035","article-title":"Lean non-alcoholic fatty liver disease (lean-Nafld) and the development of metabolic syndrome: a retrospective study","volume":"12","author":"Wang","year":"2022","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.lfs.2025.123638_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2023.100485","article-title":"From NAFLD to MASLD: updated naming and diagnosis criteria for fatty liver disease","volume":"65","author":"Rinella","year":"2024","journal-title":"J. Lipid Res."},{"issue":"2","key":"10.1016\/j.lfs.2025.123638_bb0045","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1016\/j.jhep.2023.07.017","article-title":"Confirmatory biomarker diagnostic studies are not needed when transitioning from NAFLD to MASLD","volume":"80","author":"Ratziu","year":"2024","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.lfs.2025.123638_bb0050","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1016\/j.jhep.2023.08.021","article-title":"Clinical and histological features under different nomenclatures of fatty liver disease: NAFLD, MAFLD, MASLD and MetALD","volume":"80","author":"Chen","year":"2024","journal-title":"J. Hepatol."},{"key":"10.1016\/j.lfs.2025.123638_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.123211","article-title":"Metabolic disorders, inter-organ crosstalk, and inflammation in the progression of metabolic dysfunction-associated steatotic liver disease","volume":"359","author":"Wang","year":"2024","journal-title":"Life Sci."},{"key":"10.1016\/j.lfs.2025.123638_bb0060","doi-asserted-by":"crossref","first-page":"1111430","DOI":"10.3389\/fendo.2023.1111430","article-title":"Response to pioglitazone in non-alcoholic fatty liver disease patients with vs. without type 2 diabetes: a meta-analysis of randomized controlled trials","volume":"14","author":"Wang","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"10.1016\/j.lfs.2025.123638_bb0065","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/jgf2.723","article-title":"Empagliflozin add-on therapy is superior to metformin monotherapy in diabetic patients with NAFLD: an open-label, single-center, pilot clinical trial","volume":"25","author":"Esmaeili","year":"2024","journal-title":"J Gen Fam Med"},{"issue":"12","key":"10.1016\/j.lfs.2025.123638_bb0070","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1038\/s41401-024-01389-3","article-title":"SGLT2 inhibitors ameliorate NAFLD in mice via downregulating PFKFB3, suppressing glycolysis and modulating macrophage polarization","volume":"45","author":"Lin","year":"2024","journal-title":"Acta Pharmacol. Sin."},{"issue":"5","key":"10.1016\/j.lfs.2025.123638_bb0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0302155","article-title":"Semaglutide combined with empagliflozin vs. monotherapy for non-alcoholic fatty liver disease in type 2 diabetes: study protocol for a randomized clinical trial","volume":"19","author":"Lin","year":"2024","journal-title":"PloS One"},{"issue":"1","key":"10.1016\/j.lfs.2025.123638_bb0080","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26010306","article-title":"NAFLD and NAFLD related HCC: emerging treatments and clinical trials","volume":"26","author":"Khare","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.lfs.2025.123638_bb0085","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/TP.0000000000002480","article-title":"Nonalcoholic fatty liver disease: basic Pathogenetic mechanisms in the progression from NAFLD to NASH","volume":"103","author":"Pierantonelli","year":"2019","journal-title":"Transplantation"},{"key":"10.1016\/j.lfs.2025.123638_bb0090","doi-asserted-by":"crossref","first-page":"1087260","DOI":"10.3389\/fendo.2022.1087260","article-title":"Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)","volume":"13","author":"Rong","year":"2022","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"9","key":"10.1016\/j.lfs.2025.123638_bb0095","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.4254\/wjh.v14.i9.1718","article-title":"Therapies for non-alcoholic fatty liver disease: a 2022 update","volume":"14","author":"Shen","year":"2022","journal-title":"World J. Hepatol."},{"issue":"1, Supplement","key":"10.1016\/j.lfs.2025.123638_bb0100","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","article-title":"NAFLD: a multisystem disease","volume":"62","author":"Byrne","year":"2015","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.lfs.2025.123638_bb0105","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.3390\/nu13051442","article-title":"Overview of non-alcoholic fatty liver disease (NAFLD) and the role of sugary food consumption and other dietary components in its development","volume":"13","author":"Vancells Lujan","year":"2021","journal-title":"Nutrients"},{"issue":"11","key":"10.1016\/j.lfs.2025.123638_bb0110","doi-asserted-by":"crossref","DOI":"10.3390\/metabo11110751","article-title":"Non-invasive analysis of human liver metabolism by magnetic resonance spectroscopy","volume":"11","author":"Jones","year":"2021","journal-title":"Metabolites"},{"issue":"9","key":"10.1016\/j.lfs.2025.123638_bb0115","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/imj.14709","article-title":"Non-alcoholic fatty liver disease: a review of epidemiology, risk factors, diagnosis and management","volume":"50","author":"Huang","year":"2020","journal-title":"Intern. Med. J."},{"key":"10.1016\/j.lfs.2025.123638_bb0120","doi-asserted-by":"crossref","first-page":"3920196","DOI":"10.1155\/2020\/3920196","article-title":"The intricate relationship between type 2 diabetes mellitus (T2DM), insulin resistance (IR), and nonalcoholic fatty liver disease (NAFLD)","volume":"2020","author":"Tanase","year":"2020","journal-title":"J. Diabetes Res."},{"issue":"11","key":"10.1016\/j.lfs.2025.123638_bb0125","article-title":"The role of insulin resistance and diabetes in nonalcoholic fatty liver disease","volume":"21","author":"Fujii, H., N. Kawada, and J.-N. Japan Study Group Of Nafld","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.lfs.2025.123638_bb0130","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20020298","article-title":"Homeostasis of glucose and lipid in non-alcoholic fatty liver disease","volume":"20","author":"Chao","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.lfs.2025.123638_bb0135","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jceh.2018.10.004","article-title":"Molecular and pathological events involved in the pathogenesis of diabetes-associated nonalcoholic fatty liver disease","volume":"9","author":"Bedi","year":"2019","journal-title":"J. Clin. Exp. Hepatol."},{"issue":"8","key":"10.1016\/j.lfs.2025.123638_bb0140","doi-asserted-by":"crossref","first-page":"4156","DOI":"10.3390\/ijms22084156","article-title":"Role of insulin resistance in MAFLD","volume":"22","author":"Yoshitaka Sakurai","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.lfs.2025.123638_bb0145","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nrgastro.2017.32","article-title":"Lipid droplets and liver disease: from basic biology to clinical implications","volume":"14","author":"Gluchowski","year":"2017","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"4","key":"10.1016\/j.lfs.2025.123638_bb0150","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1152\/physrev.00063.2017","article-title":"Mechanisms of insulin action and insulin resistance","volume":"98","author":"Petersen","year":"2018","journal-title":"Physiol. Rev."},{"issue":"4","key":"10.1016\/j.lfs.2025.123638_bb0155","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/lipd.12244","article-title":"Relationships between very low-density lipoproteins-ceramides, -diacylglycerols, and -Triacylglycerols in insulin-resistant men","volume":"55","author":"Mucinski","year":"2020","journal-title":"Lipids"},{"issue":"4","key":"10.1016\/j.lfs.2025.123638_bb0160","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.livres.2023.11.003","article-title":"In-depth analysis of de novo lipogenesis in non-alcoholic fatty liver disease: mechanism and pharmacological interventions","volume":"7","author":"Zhu","year":"2023","journal-title":"Liver Research"},{"issue":"9","key":"10.1016\/j.lfs.2025.123638_bb0165","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.bbagrm.2016.03.002","article-title":"Nuclear receptors and nonalcoholic fatty liver disease","volume":"1859","author":"Cave","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"issue":"10","key":"10.1016\/j.lfs.2025.123638_bb0170","doi-asserted-by":"crossref","DOI":"10.3390\/nu10101383","article-title":"Regulation and metabolic significance of De novo lipogenesis in adipose tissues","volume":"10","author":"Song","year":"2018","journal-title":"Nutrients"},{"issue":"7","key":"10.1016\/j.lfs.2025.123638_bb0175","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1111\/jcmm.13636","article-title":"The TLR4-IRE1\u03b1 pathway activation contributes to palmitate-elicited lipotoxicity in hepatocytes","volume":"22","author":"Shen","year":"2018","journal-title":"J. Cell. Mol. Med."},{"issue":"1","key":"10.1016\/j.lfs.2025.123638_bb0180","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12865-020-00358-9","article-title":"Anti-inflammatory activity of berberine in non-alcoholic fatty liver disease via the Angptl2 pathway","volume":"21","author":"Lu","year":"2020","journal-title":"BMC Immunol."},{"issue":"4","key":"10.1016\/j.lfs.2025.123638_bb0185","article-title":"The effects of anti-TNF-\u03b1 biologics on insulin resistance and insulin sensitivity in patients with rheumatoid arthritis: an update systematic review and meta-analysis","volume":"18","author":"Wei Shyann Lim","year":"2024","journal-title":"Diabetes Metab. Syndr."},{"issue":"2","key":"10.1016\/j.lfs.2025.123638_bb0190","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3390\/nu16020294","article-title":"Improving the effect of ferulic acid on inflammation and insulin resistance by regulating the JNK\/ERK and NF-\u03baB pathways in TNF-\u03b1-treated 3T3-L1 adipocytes","volume":"16","author":"Jae-Eun Park","year":"2024","journal-title":"Nutrients"},{"key":"10.1016\/j.lfs.2025.123638_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101349","article-title":"The hepatocyte IKK:NF-\u03baB axis promotes liver steatosis by stimulating de novo lipogenesis and cholesterol synthesis","volume":"54","author":"Heida","year":"2021","journal-title":"Mol Metab"},{"issue":"3","key":"10.1016\/j.lfs.2025.123638_bb0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0149677","article-title":"Blocking nuclear factor-kappa B protects against diet-induced hepatic steatosis and insulin resistance in mice","volume":"11","author":"Zeng","year":"2016","journal-title":"PloS One"},{"issue":"4","key":"10.1016\/j.lfs.2025.123638_bb0205","doi-asserted-by":"crossref","DOI":"10.3390\/nu9040387","article-title":"Nonalcoholic fatty liver disease and insulin resistance: new insights and potential new treatments","volume":"9","author":"Kitade","year":"2017","journal-title":"Nutrients"},{"issue":"2","key":"10.1016\/j.lfs.2025.123638_bb0210","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nm.2279","article-title":"The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance","volume":"17","author":"Vandanmagsar","year":"2011","journal-title":"Nat. Med."},{"issue":"10","key":"10.1016\/j.lfs.2025.123638_bb0215","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1007\/s00109-014-1170-1","article-title":"NLRP3 inflammasome activation is required for fibrosis development in NAFLD","volume":"92","author":"Wree","year":"2014","journal-title":"J. Mol. Med. (Berl)"},{"issue":"5","key":"10.1016\/j.lfs.2025.123638_bb0220","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/apm.12155","article-title":"Mechanism of interleukin-1\u03b2-induced proliferation in rat hepatic stellate cells from different levels of signal transduction","volume":"122","author":"Yaping","year":"2014","journal-title":"Apmis"},{"issue":"5","key":"10.1016\/j.lfs.2025.123638_bb0225","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jhep.2017.01.022","article-title":"NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice","volume":"66","author":"Mridha","year":"2017","journal-title":"J. Hepatol."},{"issue":"22","key":"10.1016\/j.lfs.2025.123638_bb0230","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222212413","article-title":"MyD88 in macrophages enhances liver fibrosis by activation of NLRP3 Inflammasome in HSCs","volume":"22","author":"Ge","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.lfs.2025.123638_bb0235","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.bbrc.2018.09.055","article-title":"NLRP3 inflammasome activation in liver cirrhotic patients","volume":"505","author":"Ma","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.lfs.2025.123638_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154797","article-title":"A new mechanism of obeticholic acid on NASH treatment by inhibiting NLRP3 inflammasome activation in macrophage","volume":"120","author":"Huang","year":"2021","journal-title":"Metabolism"},{"issue":"2","key":"10.1016\/j.lfs.2025.123638_bb0245","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00109-020-02032-4","article-title":"NLRP3 inflammasome priming and activation in cholestatic liver injury via the sphingosine 1-phosphate\/S1P receptor 2\/g\u03b1((12\/13))\/MAPK signaling pathway","volume":"99","author":"Hou","year":"2021","journal-title":"J. Mol. Med. (Berl)"},{"issue":"5","key":"10.1016\/j.lfs.2025.123638_bb0250","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.cmet.2015.04.004","article-title":"Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis","volume":"21","author":"Koliaki","year":"2015","journal-title":"Cell Metab."},{"issue":"17","key":"10.1016\/j.lfs.2025.123638_bb0255","doi-asserted-by":"crossref","first-page":"4192","DOI":"10.7150\/thno.21400","article-title":"Pro-inflammatory CXCR3 impairs mitochondrial function in experimental non-alcoholic steatohepatitis","volume":"7","author":"Du","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.lfs.2025.123638_bb0260","doi-asserted-by":"crossref","first-page":"6889533","DOI":"10.1155\/2021\/6889533","article-title":"The role and mechanism of oxidative stress and nuclear receptors in the development of NAFLD","volume":"2021","author":"Hong","year":"2021","journal-title":"Oxid. Med. Cell. Longev."},{"issue":"3","key":"10.1016\/j.lfs.2025.123638_bb0265","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1053\/j.gastro.2018.06.083","article-title":"Mitochondrial dysfunction and signaling in chronic liver diseases","volume":"155","author":"Mansouri","year":"2018","journal-title":"Gastroenterology"},{"issue":"165838","key":"10.1016\/j.lfs.2025.123638_bb0270","article-title":"Mitochondrial dysfunction in metabolic syndrome. Biochimica et biophysica acta","volume":"1866","author":"Prasun","year":"2020","journal-title":"Mol. Basis Dis."},{"key":"10.1016\/j.lfs.2025.123638_bb0275","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.freeradbiomed.2020.02.025","article-title":"Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease","volume":"152","author":"Chen","year":"2020","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.lfs.2025.123638_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155663","article-title":"Uroguanylin prevents hepatic steatosis, mitochondrial dysfunction and fibrosis in obesity-associated NAFLD","volume":"147","author":"Fern\u00e1ndez-S\u00e1ez","year":"2023","journal-title":"Metabolism"},{"key":"10.1016\/j.lfs.2025.123638_bb0285","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.freeradbiomed.2022.06.226","article-title":"Nonalcoholic steatohepatitis and mechanisms by which it is ameliorated by activation of the CNC-bZIP transcription factor Nrf2","volume":"188","author":"Bathish","year":"2022","journal-title":"Free Radic. Biol. Med."},{"issue":"3","key":"10.1016\/j.lfs.2025.123638_bb0290","doi-asserted-by":"crossref","first-page":"G205","DOI":"10.1152\/ajpgi.00270.2015","article-title":"Defect of mitochondrial respiratory chain is a mechanism of ROS overproduction in a rat model of alcoholic liver disease: role of zinc deficiency","volume":"310","author":"Sun","year":"2016","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"39","key":"10.1016\/j.lfs.2025.123638_bb0295","doi-asserted-by":"crossref","first-page":"14205","DOI":"10.3748\/wjg.v20.i39.14205","article-title":"Oxidative stress, cardiolipin and mitochondrial dysfunction in nonalcoholic fatty liver disease","volume":"20","author":"Paradies","year":"2014","journal-title":"World J. Gastroenterol."},{"issue":"11","key":"10.1016\/j.lfs.2025.123638_bb0300","doi-asserted-by":"crossref","DOI":"10.3390\/nu12113472","article-title":"Physiopathology of lifestyle interventions in non-alcoholic fatty liver disease (NAFLD)","volume":"12","author":"Carneros","year":"2020","journal-title":"Nutrients"},{"issue":"19","key":"10.1016\/j.lfs.2025.123638_bb0305","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.3748\/wjg.v24.i19.2083","article-title":"Mediterranean diet and nonalcoholic fatty liver disease","volume":"24","author":"Anania","year":"2018","journal-title":"World J. Gastroenterol."},{"issue":"16","key":"10.1016\/j.lfs.2025.123638_bb0310","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.4254\/wjh.v7.i16.2041","article-title":"Physical activity as a treatment of non-alcoholic fatty liver disease: a systematic review","volume":"7","author":"Whitsett","year":"2015","journal-title":"World J. Hepatol."},{"issue":"5","key":"10.1016\/j.lfs.2025.123638_bb0315","doi-asserted-by":"crossref","first-page":"G874","DOI":"10.1152\/ajpgi.00510.2010","article-title":"Daily exercise vs. caloric restriction for prevention of nonalcoholic fatty liver disease in the OLETF rat model","volume":"300","author":"Rector","year":"2011","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"1","key":"10.1016\/j.lfs.2025.123638_bb0320","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1038\/s41598-018-38321-9","article-title":"Voluntary exercise in mice fed an obesogenic diet alters the hepatic immune phenotype and improves metabolic parameters \u2013 an animal model of life style intervention in NAFLD","volume":"9","author":"Gehrke","year":"2019","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.lfs.2025.123638_bb0325","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12902-022-00980-1","article-title":"Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss","volume":"22","author":"Pouwels","year":"2022","journal-title":"BMC Endocr. Disord."},{"issue":"1","key":"10.1016\/j.lfs.2025.123638_bb0330","doi-asserted-by":"crossref","first-page":"9030","DOI":"10.1038\/s41598-017-09702-3","article-title":"Pioglitazone enhances cytosolic lipolysis, \u03b2-oxidation and autophagy to ameliorate hepatic steatosis","volume":"7","author":"Hsiao","year":"2017","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.lfs.2025.123638_bb0335","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/j.1365-2036.2010.04405.x","article-title":"Pioglitazone in the treatment of NASH: the role of adiponectin","volume":"32","author":"Gastaldelli","year":"2010","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.lfs.2025.123638_bb0340","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann. Intern. Med."},{"issue":"8","key":"10.1016\/j.lfs.2025.123638_bb0345","doi-asserted-by":"crossref","DOI":"10.3390\/biom13081199","article-title":"Combination of pioglitazone and metformin actions on liver lipid metabolism in obese mice","volume":"13","author":"Liu","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.lfs.2025.123638_bb0350","doi-asserted-by":"crossref","first-page":"44612","DOI":"10.1038\/srep44612","article-title":"Effect of modulation of PPAR-\u03b3 activity on Kupffer cells M1\/M2 polarization in the development of non-alcoholic fatty liver disease","volume":"7","author":"Luo","year":"2017","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.lfs.2025.123638_bb0355","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1186\/s12916-023-03129-6","article-title":"Comparative effectiveness of multiple different treatment regimens for nonalcoholic fatty liver disease with type 2 diabetes mellitus: a systematic review and Bayesian network meta-analysis of randomised controlled trials","volume":"21","author":"Deng","year":"2023","journal-title":"BMC Med."},{"key":"10.1016\/j.lfs.2025.123638_bb0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol Metab"},{"issue":"2","key":"10.1016\/j.lfs.2025.123638_bb0365","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24021703","article-title":"GLP-1 receptor agonists in non-alcoholic fatty liver disease: current evidence and future perspectives","volume":"24","author":"Nevola","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2025.123638_bb0370","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/S0140-6736(14)60284-1","article-title":"Effect of liraglutide on adipose insulin resistance and hepatic de-novo lipogenesis in non-alcoholic steatohepatitis: substudy of a phase 2, randomised placebo-controlled trial","volume":"383","author":"Armstrong","year":"2014","journal-title":"Lancet"},{"issue":"10019","key":"10.1016\/j.lfs.2025.123638_bb0375","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.lfs.2025.123638_bb0380","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous Semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.lfs.2025.123638_bb0385","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.jhep.2010.09.032","article-title":"Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase","volume":"54","author":"Ben-Shlomo","year":"2011","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.lfs.2025.123638_bb0390","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s00125-016-3896-5","article-title":"GLP-1 receptor agonist promotes brown remodelling in mouse white adipose tissue through SIRT1","volume":"59","author":"Xu","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.lfs.2025.123638_bb0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117725","article-title":"Exenatide ameliorates experimental non-alcoholic fatty liver in rats via suppression of toll-like receptor 4\/NF\u03baB signaling: comparison to metformin","volume":"253","author":"Saad","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.lfs.2025.123638_bb0400","article-title":"Exenatide attenuates non-alcoholic steatohepatitis by inhibiting the Pyroptosis signaling pathway","volume":"12","author":"Liu","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.lfs.2025.123638_bb0405","article-title":"Liraglutide attenuates hepatic ischemia-reperfusion injury by modulating macrophage polarization","volume":"13","author":"Li","year":"2022","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.lfs.2025.123638_bb0410","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1001\/jamainternmed.2024.4661","article-title":"GLP-1 receptor agonists and risk for cirrhosis and related complications in patients with metabolic dysfunction-associated Steatotic liver disease","volume":"184","author":"Kanwal","year":"2024","journal-title":"JAMA Intern. Med."},{"issue":"6","key":"10.1016\/j.lfs.2025.123638_bb0415","doi-asserted-by":"crossref","first-page":"867","DOI":"10.37349\/eds.2024.00078","article-title":"FDA's approval of resmetirom (Rezdiffra): a breakthrough in MASH management","volume":"2","author":"Azam","year":"2024","journal-title":"Explor. Drug Sci."},{"issue":"5","key":"10.1016\/j.lfs.2025.123638_bb0420","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrendo.2018.10","article-title":"Direct effects of thyroid hormones on hepatic lipid metabolism","volume":"14","author":"Sinha","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"issue":"6","key":"10.1016\/j.lfs.2025.123638_bb0425","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s40265-024-02045-0","article-title":"Resmetirom: first approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"issue":"24","key":"10.1016\/j.lfs.2025.123638_bb0430","doi-asserted-by":"crossref","first-page":"17380","DOI":"10.3390\/ijms242417380","article-title":"Improved Glycaemic control and Nephroprotective effects of Empagliflozin and Paricalcitol co-therapy in mice with type 2 diabetes mellitus","volume":"24","author":"Mujalli","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.lfs.2025.123638_bb0435","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of Resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"10213","key":"10.1016\/j.lfs.2025.123638_bb0440","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.lfs.2025.123638_bb0445","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.tips.2024.08.009","article-title":"Rezdiffra\u2122 (resmetirom): a THR-\u03b2 agonist for non-alcoholic steatohepatitis","volume":"45","author":"Brisnovali","year":"2024","journal-title":"Trends Pharmacol. Sci."},{"issue":"3","key":"10.1016\/j.lfs.2025.123638_bb0450","doi-asserted-by":"crossref","first-page":"161","DOI":"10.4103\/2229-516X.165363","article-title":"Sodium glucose co-transporter inhibitors - a new class of old drugs","volume":"5","author":"Malhotra","year":"2015","journal-title":"Int. J. Appl. Basic Med. Res."},{"issue":"5","key":"10.1016\/j.lfs.2025.123638_bb0455","first-page":"541","article-title":"Effect of phlorizin on SGLT2 expression in the kidney of diabetic rats","volume":"23","author":"Osorio","year":"2010","journal-title":"J. Nephrol."},{"issue":"2","key":"10.1016\/j.lfs.2025.123638_bb0460","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3390\/nu8020092","article-title":"Phlorizin supplementation attenuates obesity, inflammation, and hyperglycemia in diet-induced obese mice fed a high-fat diet","volume":"8","author":"Shin","year":"2016","journal-title":"Nutrients"},{"issue":"1","key":"10.1016\/j.lfs.2025.123638_bb0465","doi-asserted-by":"crossref","DOI":"10.1016\/j.phyplu.2021.100200","article-title":"Therapeutic indication of Phloridzin: a new gleam for metabolic disorders","volume":"2","author":"Khanam","year":"2022","journal-title":"Phytomedicine Plus"},{"issue":"1","key":"10.1016\/j.lfs.2025.123638_bb0470","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/dmrr.532","article-title":"Phlorizin: a review","volume":"21","author":"Ehrenkranz","year":"2005","journal-title":"Diabetes Metab. Res. Rev."},{"issue":"12\u221213","key":"10.1016\/j.lfs.2025.123638_bb0475","first-page":"985","article-title":"Natural products as Lead compounds for sodium glucose cotransporter (SGLT) inhibitors","volume":"83","author":"Blaschek","year":"2017","journal-title":"Planta Med."},{"issue":"4","key":"10.1016\/j.lfs.2025.123638_bb0480","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1021\/acs.oprd.8b00017","article-title":"Synthetic strategies toward SGLT2 inhibitors","volume":"22","author":"Aguill\u00f3n","year":"2018","journal-title":"Org. Process Res. Dev."},{"issue":"12","key":"10.1016\/j.lfs.2025.123638_bb0485","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.34067\/KID.0002772021","article-title":"SGLT2 inhibitors: physiology and pharmacology","volume":"2","author":"Wright","year":"2021","journal-title":"Kidney360"},{"key":"10.1016\/j.lfs.2025.123638_bb0490","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.2147\/DMSO.S240903","article-title":"SGLT2 inhibitors in the management of type 1 diabetes (T1D): an update on current evidence and recommendations","volume":"16","author":"Maffei","year":"2023","journal-title":"Diab. Metab. Syndr. Obes."},{"issue":"4","key":"10.1016\/j.lfs.2025.123638_bb0495","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3109\/07853890.2011.560181","article-title":"A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials","volume":"44","author":"Musso","year":"2012","journal-title":"Ann. Med."},{"issue":"9","key":"10.1016\/j.lfs.2025.123638_bb0500","doi-asserted-by":"crossref","first-page":"4959","DOI":"10.3390\/ijms25094959","article-title":"SGLT2 inhibitors in kidney diseases\u2014a narrative review","volume":"25","author":"Gajewska","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.lfs.2025.123638_bb0505","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s40200-024-01406-6","article-title":"Narrative review of data supporting alternate first-line therapies over metformin in type 2 diabetes","volume":"23","author":"Andraos","year":"2024","journal-title":"J. Diabetes Metab. Disord."},{"issue":"5","key":"10.1016\/j.lfs.2025.123638_bb0510","doi-asserted-by":"crossref","DOI":"10.3390\/nu13051442","article-title":"Overview of non-alcoholic fatty liver disease (NAFLD) and the role of sugary food consumption and other dietary components in its development","volume":"13","author":"Vancells Lujan","year":"2021","journal-title":"Nutrients"},{"issue":"1","key":"10.1016\/j.lfs.2025.123638_bb0515","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s12551-015-0186-2","article-title":"Glucose transporters: physiological and pathological roles","volume":"8","author":"Navale","year":"2016","journal-title":"Biophys. Rev."},{"issue":"2","key":"10.1016\/j.lfs.2025.123638_bb0520","doi-asserted-by":"crossref","first-page":"G241","DOI":"10.1152\/ajpgi.00310.2001","article-title":"Expression of monosaccharide transporters in intestine of diabetic humans","volume":"282","author":"Dyer","year":"2002","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"3","key":"10.1016\/j.lfs.2025.123638_bb0525","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1002\/oby.23653","article-title":"Obesity and overweight are linked to increased sodium-glucose cotransporter 1 and glucose transporter 5 levels in duodenum","volume":"31","author":"Fiorentino","year":"2023","journal-title":"Obesity (Silver Spring)"},{"issue":"5","key":"10.1016\/j.lfs.2025.123638_bb0530","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1172\/JCI112981","article-title":"Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats","volume":"79","author":"Rossetti","year":"1987","journal-title":"J. Clin. Invest."},{"issue":"12","key":"10.1016\/j.lfs.2025.123638_bb0535","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.2337\/diabetes.54.12.3427","article-title":"Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes","volume":"54","author":"Rahmoune","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.lfs.2025.123638_bb0540","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.2147\/DMSO.S269916","article-title":"Comparative analysis of the preventive effects of canagliflozin, a sodium-glucose co-transporter-2 inhibitor, on body weight gain between oral gavage and dietary administration by focusing on fatty acid metabolism","volume":"13","author":"Kawarasaki","year":"2020","journal-title":"Diabetes Metab. Syndr. Obes."},{"issue":"11","key":"10.1016\/j.lfs.2025.123638_bb0545","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1007\/s00592-020-01558-w","article-title":"Expression of glucose transporters in duodenal mucosa of patients with type 1 diabetes","volume":"57","author":"Bolla","year":"2020","journal-title":"Acta Diabetol."},{"issue":"12","key":"10.1016\/j.lfs.2025.123638_bb0550","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.3109\/00498254.2015.1042947","article-title":"Preclinical metabolism and disposition of luseogliflozin, a novel antihyperglycemic agent","volume":"45","author":"Hasegawa","year":"2015","journal-title":"Xenobiotica"},{"issue":"4","key":"10.1016\/j.lfs.2025.123638_bb0555","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s00795-022-00334-9","article-title":"Hepatic expression of sodium\u2013glucose cotransporter 2 (SGLT2) in patients with chronic liver disease","volume":"55","author":"Nakano","year":"2022","journal-title":"Med. Mol. Morphol."},{"issue":"8","key":"10.1016\/j.lfs.2025.123638_bb0560","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1002\/ijc.31193","article-title":"Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake","volume":"142","author":"Kaji","year":"2018","journal-title":"Int. J. Cancer"},{"issue":"8","key":"10.1016\/j.lfs.2025.123638_bb0565","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.3168\/jds.S0022-0302(05)72953-2","article-title":"Cloning and expression of bovine sodium\/glucose cotransporter SGLT2","volume":"88","author":"Zhao","year":"2005","journal-title":"J. Dairy Sci."},{"issue":"4","key":"10.1016\/j.lfs.2025.123638_bb0570","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0232283","article-title":"Effects of canagliflozin on growth and metabolic reprograming in hepatocellular carcinoma cells: multi-omics analysis of metabolomics and absolute quantification proteomics (iMPAQT)","volume":"15","author":"Nakano","year":"2020","journal-title":"PloS One"},{"key":"10.1016\/j.lfs.2025.123638_bb0575","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155612","article-title":"Increased expression of sodium-glucose cotransporter 2 and O-GlcNAcylation in hepatocytes drives non-alcoholic steatohepatitis","volume":"145","author":"Chun","year":"2023","journal-title":"Metabolism"},{"key":"10.1016\/j.lfs.2025.123638_bb0580","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.155914","article-title":"O-GlcNAcylation promotes the progression of nonalcoholic fatty liver disease by upregulating the expression and function of CD36","volume":"156","author":"Zhu","year":"2024","journal-title":"Metabolism"},{"issue":"1","key":"10.1016\/j.lfs.2025.123638_bb0585","doi-asserted-by":"crossref","first-page":"E30","DOI":"10.1152\/ajpendo.00257.2020","article-title":"GPR40 deficiency is associated with hepatic FAT\/CD36 upregulation, steatosis, inflammation, and cell injury in C57BL\/6 mice","volume":"320","author":"Lu","year":"2021","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.lfs.2025.123638_bb0590","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s13098-018-0395-5","article-title":"Anti-inflammatory effects of empagliflozin in patients with type 2 diabetes and insulin resistance","volume":"10","author":"Hattori","year":"2018","journal-title":"Diabetol. Metab. Syndr."},{"issue":"7","key":"10.1016\/j.lfs.2025.123638_bb0595","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23073668","article-title":"SGLT2 inhibitors as the Most promising influencers on the outcome of non-alcoholic fatty liver disease","volume":"23","author":"Mirarchi","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.lfs.2025.123638_bb0600","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s11154-014-9298-4","article-title":"Pharmacological treatment and therapeutic perspectives of metabolic syndrome","volume":"15","author":"Soo Lim","year":"2014","journal-title":"Rev. Endocr. Metab. Disord."},{"issue":"2","key":"10.1016\/j.lfs.2025.123638_bb0605","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s11892-010-0095-5","article-title":"Turning glucosuria into a therapy: efficacy and safety with SGLT2 inhibitors","volume":"10","author":"Anupa K. Patel, V.F","year":"2010","journal-title":"Curr. Diab. Rep."},{"key":"10.1016\/j.lfs.2025.123638_bb0610","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111315","article-title":"Adipose tissue and insulin resistance in obese","volume":"137","author":"Ahmed","year":"2021","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.lfs.2025.123638_bb0615","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4093\/dmj.2021.0280","article-title":"Insulin resistance: from mechanisms to therapeutic strategies","volume":"46","author":"Lee","year":"2022","journal-title":"Diabetes Metab. J."},{"issue":"40","key":"10.1016\/j.lfs.2025.123638_bb0620","doi-asserted-by":"crossref","first-page":"7502","DOI":"10.1021\/acs.jafc.6b03474","article-title":"Insulin sensitivity-enhancing activity of Phlorizin is associated with lipopolysaccharide decrease and gut microbiota changes in obese and type 2 diabetes (db\/db) mice","volume":"64","author":"Mei","year":"2016","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.lfs.2025.123638_bb0625","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2020.114997","article-title":"Effects of dapagliflozin and statins attenuate renal injury and liver steatosis in high-fat\/high-fructose diet-induced insulin resistant rats","volume":"396","author":"Thongnak","year":"2020","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"11","key":"10.1016\/j.lfs.2025.123638_bb0630","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1007\/s12325-020-01498-5","article-title":"Effect of empagliflozin on liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease without diabetes: a randomized, double-blind, Placebo-Controlled Trial","volume":"37","author":"Taheri","year":"2020","journal-title":"Adv. Ther."},{"issue":"1","key":"10.1016\/j.lfs.2025.123638_bb0635","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1186\/s12876-023-02948-4","article-title":"Effect of Empagliflozin and pioglitazone on left ventricular function in patients with type two diabetes and nonalcoholic fatty liver disease without established cardiovascular disease: a randomized single-blind clinical trial","volume":"23","author":"Attaran","year":"2023","journal-title":"BMC Gastroenterol."},{"issue":"2","key":"10.1016\/j.lfs.2025.123638_bb0640","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s10620-019-5477-1","article-title":"Empagliflozin for the treatment of nonalcoholic steatohepatitis in patients with type 2 diabetes mellitus","volume":"65","author":"Lai","year":"2020","journal-title":"Dig. Dis. Sci."},{"issue":"3","key":"10.1016\/j.lfs.2025.123638_bb0645","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s13300-021-01014-0","article-title":"Efficacy and safety of luseogliflozin in patients with type 2 diabetes complicated by hepatic dysfunction: a single-site, single-arm, open-label, Exploratory Trial","volume":"12","author":"Seino","year":"2021","journal-title":"Diabetes Ther."},{"issue":"5","key":"10.1016\/j.lfs.2025.123638_bb0650","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.13335","article-title":"Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"73","author":"Aso","year":"2019","journal-title":"Int. J. Clin. Pract."},{"issue":"1","key":"10.1016\/j.lfs.2025.123638_bb0655","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2020-001990","article-title":"Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial","volume":"9","author":"Yoneda","year":"2021","journal-title":"BMJ Open Diabetes Res. Care"},{"issue":"3","key":"10.1016\/j.lfs.2025.123638_bb0660","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s13300-021-01011-3","article-title":"Empagliflozin improves liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, Placebo-Controlled Clinical Trial","volume":"12","author":"Chehrehgosha","year":"2021","journal-title":"Diabetes Ther."},{"issue":"10","key":"10.1016\/j.lfs.2025.123638_bb0665","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc17-0518","article-title":"Comparison of ipragliflozin and pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes: a randomized, 24-week, open-label, Active-Controlled Trial","volume":"40","author":"Ito","year":"2017","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.lfs.2025.123638_bb0670","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1111\/dom.15006","article-title":"Empagliflozin versus sitagliptin for ameliorating intrahepatic lipid content and tissue-specific insulin sensitivity in patients with early-stage type 2 diabetes with non-alcoholic fatty liver disease: a prospective randomized study","volume":"25","author":"Hiruma","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.lfs.2025.123638_bb0675","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ebiom.2017.05.028","article-title":"SGLT2 inhibition by Empagliflozin promotes fat utilization and Browning and Attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice","volume":"20","author":"Xu","year":"2017","journal-title":"EBioMedicine"},{"issue":"3","key":"10.1016\/j.lfs.2025.123638_bb0680","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1210\/en.2015-1588","article-title":"Tofogliflozin improves insulin resistance in skeletal muscle and accelerates lipolysis in adipose tissue in male mice","volume":"157","author":"Obata","year":"2016","journal-title":"Endocrinology"},{"issue":"3","key":"10.1016\/j.lfs.2025.123638_bb0685","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jceh.2015.02.005","article-title":"Remogliflozin Etabonate improves fatty liver disease in diet-induced obese male mice","volume":"5","author":"Nakano","year":"2015","journal-title":"J. Clin. Exp. Hepatol."},{"issue":"2","key":"10.1016\/j.lfs.2025.123638_bb0690","doi-asserted-by":"crossref","first-page":"818","DOI":"10.3390\/ijms22020818","article-title":"Empagliflozin attenuates non-alcoholic fatty liver disease (NAFLD) in high fat diet fed ApoE(\u2212\/\u2212) mice by activating autophagy and reducing ER stress and apoptosis","volume":"22","author":"Nasiri-Ansari","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.lfs.2025.123638_bb0695","article-title":"Metabolic liver disease in diabetes - from mechanisms to clinical trials","volume":"111s","author":"Dewidar","year":"2020","journal-title":"Metabolism"},{"key":"10.1016\/j.lfs.2025.123638_bb0700","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.bbrc.2021.12.065","article-title":"Hepatoprotective effects of gemigliptin and empagliflozin in a murine model of diet-induced non-alcoholic fatty liver disease","volume":"588","author":"Lee","year":"2022","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.lfs.2025.123638_bb0705","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.2147\/DMSO.S422327","article-title":"Metabolic and hepatic effects of empagliflozin on nonalcoholic fatty liver mice","volume":"16","author":"Niu","year":"2023","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"10.1016\/j.lfs.2025.123638_bb0710","article-title":"Empagliflozin activates Sestrin2-mediated AMPK\/mTOR pathway and ameliorates lipid accumulation in obesity-related nonalcoholic fatty liver disease","volume":"13","author":"Ma","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.lfs.2025.123638_bb0715","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107492","article-title":"The SGLT2 inhibitor empagliflozin negatively regulates IL-17\/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the AMPK\/mTOR\/autophagy pathway","volume":"94","author":"Meng","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.lfs.2025.123638_bb0720","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.bcp.2018.03.013","article-title":"Canagliflozin exerts anti-inflammatory effects by inhibiting intracellular glucose metabolism and promoting autophagy in immune cells","volume":"152","author":"Xu","year":"2018","journal-title":"Biochem. Pharmacol."},{"issue":"12","key":"10.1016\/j.lfs.2025.123638_bb0725","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1038\/s41401-024-01389-3","article-title":"SGLT2 inhibitors ameliorate NAFLD in mice via downregulating PFKFB3, suppressing glycolysis and modulating macrophage polarization","volume":"45","author":"Lin","year":"2024","journal-title":"Acta Pharmacol. Sin."},{"issue":"4","key":"10.1016\/j.lfs.2025.123638_bb0730","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11892-020-1292-5","article-title":"A systematic review of cost-effectiveness of sodium-glucose cotransporter inhibitors for type 2 diabetes","volume":"20","author":"Yoshida","year":"2020","journal-title":"Curr. Diab. Rep."},{"issue":"6","key":"10.1016\/j.lfs.2025.123638_bb0735","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1007\/s13300-021-01056-4","article-title":"One year of Dapaglifozin add-on therapy ameliorates surrogate indexes of insulin resistance and adiposity in patients with type 2 diabetes mellitus","volume":"12","author":"Radellini","year":"2021","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.lfs.2025.123638_bb0740","first-page":"65","article-title":"Effectiveness of triple therapy with dapagliflozin add-on to dual therapy over 52 weeks in patients with uncontrolled type 2 diabetes mellitus in a centre of high complexity, Cali-Colombia. Archives of","author":"Joaqui","year":"2021","journal-title":"Endocrinol. Metab."},{"key":"10.1016\/j.lfs.2025.123638_bb0745","series-title":"Effect of Add-On Therapy of Dapagliflozin and Empagliflozin on Adipokines in Type 2 Diabetes Mellitus","volume":"2021","author":"Shaheer","year":"2021"},{"issue":"8","key":"10.1016\/j.lfs.2025.123638_bb0750","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of Empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.lfs.2025.123638_bb0755","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2023.102279","article-title":"Comparison between the effect of Empagliflozin and pioglitazone added to metformin in patients with type 2 diabetes and nonalcoholic fatty liver disease","volume":"48","author":"Hooshmand Gharabagh","year":"2024","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"issue":"6","key":"10.1016\/j.lfs.2025.123638_bb0760","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1111\/jdi.13279","article-title":"Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, open-label, three-arm, active control study","volume":"11","author":"Kinoshita","year":"2020","journal-title":"J Diabetes Investig"},{"issue":"7","key":"10.1016\/j.lfs.2025.123638_bb0765","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1136\/jim-2020-001621","article-title":"Serum high-molecular-weight adiponectin and response to dapagliflozin in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"69","author":"Aso","year":"2021","journal-title":"J. Invest. Med."},{"key":"10.1016\/j.lfs.2025.123638_bb0770","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.613389","article-title":"Sodium-glucose Cotransporter-2 inhibitors ameliorate liver enzyme abnormalities in Korean patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease","volume":"12","author":"Euh","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.lfs.2025.123638_bb0775","doi-asserted-by":"crossref","first-page":"6796470","DOI":"10.1155\/2022\/6796470","article-title":"Empagliflozin-metformin combination has antioxidative and anti-inflammatory properties that correlate with vascular protection in adults with type 1 diabetes","volume":"2022","author":"Jani\u0107","year":"2022","journal-title":"J. Diabetes Res."},{"issue":"22","key":"10.1016\/j.lfs.2025.123638_bb0780","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.15858","article-title":"SGLT-2 inhibitors enhance the effect of metformin to ameliorate hormonal changes and inflammatory markers in a rat PCOS model","volume":"11","author":"Mahmoud","year":"2023","journal-title":"Physiol. Rep."},{"issue":"2","key":"10.1016\/j.lfs.2025.123638_bb0785","doi-asserted-by":"crossref","DOI":"10.3892\/mmr.2022.12922","article-title":"Role of the AMPK\/SIRT1 pathway in non-alcoholic fatty liver disease (review)","volume":"27","author":"Anggreini","year":"2023","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.lfs.2025.123638_bb0790","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.120070","article-title":"Blunting p38 MAPK\u03b1 and ERK1\/2 activities by empagliflozin enhances the antifibrotic effect of metformin and augments its AMPK-induced NF-\u03baB inactivation in mice intoxicated with carbon tetrachloride","volume":"286","author":"Abdelhamid","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.lfs.2025.123638_bb0795","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112455","article-title":"Empagliflozin adjunct with metformin for the inhibition of hepatocellular carcinoma progression: emerging approach for new application","volume":"145","author":"Abdelhamid","year":"2022","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.lfs.2025.123638_bb0800","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2022.102053","article-title":"Comparative efficacy of diabetes medications on liver enzymes and fat fraction in patients with nonalcoholic fatty liver disease: a network meta-analysis(,)","volume":"47","author":"Zou","year":"2023","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"issue":"6","key":"10.1016\/j.lfs.2025.123638_bb0805","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2023.101142","article-title":"Lower prevalence of elevated liver stiffness measurements in people with type 2 diabetes taking sodium-glucose co-transporter 2 inhibitors or glucagon-like peptide-1 receptor agonists","volume":"28","author":"Gracen","year":"2023","journal-title":"Ann. Hepatol."},{"issue":"3","key":"10.1016\/j.lfs.2025.123638_bb0810","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00125-023-06057-5","article-title":"Cardiovascular and mortality outcomes with GLP-1 receptor agonists vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study","volume":"67","author":"Krishnan","year":"2024","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.lfs.2025.123638_bb0815","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1517\/14740331003623218","article-title":"Pioglitazone: side effect and safety profile","volume":"9","author":"Shah","year":"2010","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.lfs.2025.123638_bb0820","doi-asserted-by":"crossref","first-page":"1145216","DOI":"10.3389\/fphys.2023.1145216","article-title":"Beneficial and adverse effects of vitamin E on the kidney","volume":"14","author":"Baltusnikiene","year":"2023","journal-title":"Front. Physiol."},{"issue":"2","key":"10.1016\/j.lfs.2025.123638_bb0825","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jhep.2024.04.036","article-title":"A turning point in hepatology? EASL reflects on the first approved drug for MASH","volume":"81","author":"Francque","year":"2024","journal-title":"J. Hepatol."},{"issue":"11","key":"10.1016\/j.lfs.2025.123638_bb0830","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00535-021-01796-x","article-title":"Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis 2020","volume":"56","author":"Tokushige","year":"2021","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.lfs.2025.123638_bb0835","doi-asserted-by":"crossref","first-page":"1010693","DOI":"10.3389\/fcvm.2022.1010693","article-title":"Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: a brief summary","volume":"9","author":"Mascolo","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"10.1016\/j.lfs.2025.123638_bb0840","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1038\/s41598-024-52603-5","article-title":"Efficacy of sodium glucose cotransporter 2 inhibitors on hepatic fibrosis and steatosis in non-alcoholic fatty liver disease: an updated systematic review and meta-analysis","volume":"14","author":"Ong Lopez","year":"2024","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.lfs.2025.123638_bb0845","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2023.102111","article-title":"Comparison of sodium-glucose cotransporter-2 inhibitors and thiazolidinediones for management of non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"47","author":"Hameed","year":"2023","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"issue":"5","key":"10.1016\/j.lfs.2025.123638_bb0850","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1007\/s40618-023-02246-6","article-title":"Comparison of SGLT2 inhibitors vs. DPP4 inhibitors for patients with metabolic dysfunction associated fatty liver disease and diabetes mellitus","volume":"47","author":"Suzuki","year":"2024","journal-title":"J. Endocrinol. Invest."},{"issue":"3","key":"10.1016\/j.lfs.2025.123638_bb0855","doi-asserted-by":"crossref","first-page":"463","DOI":"10.4239\/wjd.v15.i3.463","article-title":"Comparative efficacy of sodium glucose cotransporter-2 inhibitors in the management of type 2 diabetes mellitus: a real-world experience","volume":"15","author":"Islam","year":"2024","journal-title":"World J. Diabetes"},{"key":"10.1016\/j.lfs.2025.123638_bb0860","article-title":"Comparative cardiovascular outcomes of SGLT2 inhibitors in type 2 diabetes mellitus: a network Meta-analysis of randomized controlled trials","volume":"13","author":"Jiang","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"10.1016\/j.lfs.2025.123638_bb0865","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2023.101643","article-title":"Cardiovascular morbidity and mortality related to non-alcoholic fatty liver disease: a systematic review and Meta-analysis","volume":"48","author":"Bisaccia","year":"2023","journal-title":"Curr. Probl. Cardiol."},{"issue":"3","key":"10.1016\/j.lfs.2025.123638_bb0870","doi-asserted-by":"crossref","first-page":"467","DOI":"10.3390\/jcm10030467","article-title":"NAFLD and cardiovascular diseases: epidemiological, mechanistic and therapeutic considerations","volume":"10","author":"Niederseer","year":"2021","journal-title":"J. Clin. Med."},{"issue":"20","key":"10.1016\/j.lfs.2025.123638_bb0875","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.013389","article-title":"SGLT-2 inhibitors in heart failure: current management, unmet needs, and therapeutic prospects","volume":"8","author":"Lam","year":"2019","journal-title":"J. Am. Heart Assoc."},{"issue":"8","key":"10.1016\/j.lfs.2025.123638_bb0880","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1111\/apt.16575","article-title":"Review article: non-alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations","volume":"54","author":"Polyzos","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.lfs.2025.123638_bb0885","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41440-022-01117-6","article-title":"Mechanisms underlying the bidirectional association between nonalcoholic fatty liver disease and hypertension","volume":"46","author":"Nakagami","year":"2023","journal-title":"Hypertens. Res."},{"issue":"6","key":"10.1016\/j.lfs.2025.123638_bb0890","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1136\/gutjnl-2017-313884","article-title":"Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases","volume":"66","author":"Adams","year":"2017","journal-title":"Gut"},{"issue":"3\u20134","key":"10.1016\/j.lfs.2025.123638_bb0895","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1900\/RDS.2014.11.202","article-title":"Adverse effects of GLP-1 receptor agonists","volume":"11","author":"Filippatos","year":"2014","journal-title":"Rev. Diabet. Stud."},{"issue":"2","key":"10.1016\/j.lfs.2025.123638_bb0900","first-page":"227","article-title":"Safety and tolerability of glucagon-like peptide-1 receptor agonists: unresolved and emerging issues","volume":"16","author":"Raccah","year":"2017","journal-title":"Expert Opin. Drug Saf."},{"issue":"1","key":"10.1016\/j.lfs.2025.123638_bb0905","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/s12933-024-02461-2","article-title":"Non-alcoholic fatty liver disease risk with GLP-1 receptor agonists and SGLT-2 inhibitors in type 2 diabetes: a nationwide nested case\u2013control study","volume":"23","author":"Chang","year":"2024","journal-title":"Cardiovasc. Diabetol."},{"issue":"11","key":"10.1016\/j.lfs.2025.123638_bb0910","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24119324","article-title":"Therapeutic mechanisms and clinical effects of glucagon-like peptide 1 receptor agonists in nonalcoholic fatty liver disease","volume":"24","author":"Lee","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.lfs.2025.123638_bb0915","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1056\/NEJMe2314365","article-title":"Selective agonists of thyroid hormone receptor Beta for the treatment of NASH","volume":"390","author":"Cusi","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.lfs.2025.123638_bb0920","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3803\/EnM.2024.203","article-title":"Selective agonists of thyroid hormone receptor Beta: promising tools for the treatment of nonalcoholic fatty liver disease","volume":"39","author":"Cho","year":"2024","journal-title":"Endocrinol. Metab. (Seoul)"}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320525002735?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320525002735?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T23:12:23Z","timestamp":1762211543000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320525002735"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":184,"alternative-id":["S0024320525002735"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2025.123638","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update in non-alcoholic fatty liver disease management: role of sodium-glucose cotransporter 2 inhibitors","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2025.123638","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"123638"}}